Guidance, NICE advice and quality standards In development

Skip to filtersSkip to results

Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme

Showing 76 to 100 of 382

TitleTypeExpected publication date
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidanceTBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Technology appraisal guidance
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]Technology appraisal guidanceTBC
DCVax-L for treating glioblastoma [ID836]Technology appraisal guidanceTBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID 3897Technology appraisal guidanceTBC
Diabetic retinopathyNICE guidelineTBC
Diabetic retinopathy - ruboxistaurin [ID382]Technology appraisal guidanceTBC
Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessmentHealth technology evaluation
Digitally enabled therapy for chronic tic disorders and Tourette SyndromeMedical technologies guidance
Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implantsInterventional procedures guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Technology appraisal guidance
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Drug eluting stents for treating coronary heart disease: late stage assessmentHealth technology evaluationTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Technology appraisal guidanceTBC
Durvalumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6220]Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]Technology appraisal guidanceTBC
Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]Technology appraisal guidanceTBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317Technology appraisal guidanceTBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725Technology appraisal guidanceTBC
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]Technology appraisal guidanceTBC
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)NICE guideline
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All